Cargando…
A Comparative Study of SMN Protein and mRNA in Blood and Fibroblasts in Patients with Spinal Muscular Atrophy and Healthy Controls
BACKGROUND: Clinical trials to test safety and efficacy of drugs for patients with spinal muscular atrophy (SMA) are currently underway. Biomarkers that document treatment-induced effects are needed because disease progression in childhood forms of SMA is slow and clinical outcome measures may lack...
Autores principales: | Wadman, Renske I., Stam, Marloes, Jansen, Marc D., van der Weegen, Yana, Wijngaarde, Camiel A., Harschnitz, Oliver, Sodaar, Peter, Braun, Kees P. J., Dooijes, Dennis, Lemmink, Henny H., van den Berg, Leonard H., van der Pol, W. Ludo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5125671/ https://www.ncbi.nlm.nih.gov/pubmed/27893852 http://dx.doi.org/10.1371/journal.pone.0167087 |
Ejemplares similares
-
Intragenic and structural variation in the SMN locus and clinical variability in spinal muscular atrophy
por: Wadman, Renske I, et al.
Publicado: (2020) -
Limited maximal mouth opening in patients with spinal muscular atrophy complicates endotracheal intubation: An observational study
por: Wijngaarde, Camiel A., et al.
Publicado: (2018) -
A continuous repetitive task to detect fatigability in spinal muscular atrophy
por: Stam, Marloes, et al.
Publicado: (2018) -
Analysis of FUS, PFN2, TDP-43, and PLS3 as potential disease severity modifiers in spinal muscular atrophy
por: Wadman, Renske I., et al.
Publicado: (2019) -
Assessment of fatigability in patients with spinal muscular atrophy: development and content validity of a set of endurance tests
por: Bartels, Bart, et al.
Publicado: (2019)